-
公开(公告)号:US08889687B2
公开(公告)日:2014-11-18
申请号:US13411198
申请日:2012-03-02
申请人: Julie F. Liu , Roger Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger Tung , Scott L. Harbeson
IPC分类号: A61K31/4985 , C07D471/04 , C07B59/00
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/4985 , C07B59/002 , Y02A50/411 , Y02A50/423
摘要: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
摘要翻译: 本发明在一个实施方案中涉及式Ia化合物; 其中指定(R)表示指定的碳具有(R)立体化学; 并且其中Z1是氢或氟; Z2是氢,氘或氟; Z3是氘; Z4是氟; m为0〜10的整数; n为0〜2的整数; 条件是:m + n的和不超过10; 并且当Z1和Z2均为氢时,m + n的和大于0,以及其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US08563554B2
公开(公告)日:2013-10-22
申请号:US13256787
申请日:2010-03-16
申请人: Julie F. Liu , Scott L. Harbeson , Roger Tung
发明人: Julie F. Liu , Scott L. Harbeson , Roger Tung
IPC分类号: A61K31/495
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/4985 , A61K45/06 , Y02A50/411 , Y02A50/423 , A61K2300/00
摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel, such as compounds of formula (I): or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮的衍生物的新的吡嗪并喹啉衍生物,例如式(I)的化合物或其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US20120149709A1
公开(公告)日:2012-06-14
申请号:US13256787
申请日:2010-03-16
申请人: Julie F. Liu , Roger Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger Tung , Scott L. Harbeson
IPC分类号: A61K31/498 , A01N43/90 , A01P15/00 , A61P33/12 , A61P33/10 , C07D471/04 , A61P33/06
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/4985 , A61K45/06 , Y02A50/411 , Y02A50/423 , A61K2300/00
摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮衍生物的新型吡嗪异喹啉衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US20130121963A1
公开(公告)日:2013-05-16
申请号:US13473302
申请日:2012-05-16
申请人: Scott L. Harbeson , Julie F. Liu , Roger Tung
发明人: Scott L. Harbeson , Julie F. Liu , Roger Tung
IPC分类号: C07D401/14 , C07D401/04 , A61K31/675 , A61K45/06 , A61K31/506 , C07F9/6558
CPC分类号: C07D401/14 , A61K31/506 , A61K31/675 , A61K45/06 , C07D401/04 , C07F9/65583
摘要: This disclosure relates to novel N-phenyl-2-pyrimidineamines and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering protein-tyrosine kinase inhibitors.
摘要翻译: 本公开涉及新的N-苯基-2-嘧啶胺及其药学上可接受的盐。 本公开还提供了包含本公开的化合物的组合物以及这些组合物在治疗通过施用蛋白质 - 酪氨酸激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US20130029997A1
公开(公告)日:2013-01-31
申请号:US13411198
申请日:2012-03-02
申请人: Julie F. Liu , Roger Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger Tung , Scott L. Harbeson
IPC分类号: A61K31/4985 , A61P33/02 , A61P33/10 , A61P33/06 , C07D471/04 , A61P33/12
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/4985 , C07B59/002 , Y02A50/411 , Y02A50/423
摘要: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
-
公开(公告)号:US20100221221A1
公开(公告)日:2010-09-02
申请号:US12539091
申请日:2009-08-11
申请人: Scott L. Harbeson , Julie F. Liu , Roger Tung
发明人: Scott L. Harbeson , Julie F. Liu , Roger Tung
IPC分类号: A61K38/21 , C07D401/14 , A61K31/506 , A61P35/02 , A61P35/00 , A61P33/06 , A61P35/04 , A61P27/14 , A61P19/02 , A61P13/12 , A61P15/00 , A61P17/06 , A61P3/10 , A61P9/10 , A61P17/10 , A61P31/12 , A61P13/06 , A61P31/18 , A61K39/395 , C12N5/02 , A61K31/55 , A61K38/50 , A61K31/661 , A61K31/7068 , A61K35/12 , A61K33/24
CPC分类号: C07D401/14 , A61K31/506 , A61K31/675 , A61K45/06 , C07D401/04 , C07F9/65583
摘要: This disclosure relates to novel N-phenyl-2-pyrimidineamines and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering protein-tyrosine kinase inhibitors.
摘要翻译: 本公开涉及新的N-苯基-2-嘧啶胺及其药学上可接受的盐。 本公开还提供了包含本公开的化合物的组合物以及这些组合物在治疗通过施用蛋白质 - 酪氨酸激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US08354557B2
公开(公告)日:2013-01-15
申请号:US12456507
申请日:2009-06-17
申请人: Julie F. Liu , Xuejun Tang , Scott L. Harbeson , Craig E. Masse
发明人: Julie F. Liu , Xuejun Tang , Scott L. Harbeson , Craig E. Masse
IPC分类号: C07C215/68
CPC分类号: C07D413/10 , A61K31/5377 , A61K45/06 , C07B2200/05 , C07C215/12 , C07D263/06 , C07D295/02 , C07D295/033 , C07D295/06 , C07D295/12 , C07D295/135 , C07D413/14
摘要: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
摘要翻译: 本发明涉及一种制备由结构式(I)表示的2,26,6-d4-吗啉衍生物或其盐的方法。
-
公开(公告)号:US20100160247A1
公开(公告)日:2010-06-24
申请号:US12456507
申请日:2009-06-17
申请人: Julie F. Liu , Xuejun Tang , Scott L. Harbeson , Craig E. Masse
发明人: Julie F. Liu , Xuejun Tang , Scott L. Harbeson , Craig E. Masse
IPC分类号: A61K31/5377 , C07C215/68 , C07D265/30 , C07D413/10 , A61K31/7036 , A61K31/397 , A61P31/06 , A61P31/04 , A61P31/10 , A61K31/546 , A61K31/5383
CPC分类号: C07D413/10 , A61K31/5377 , A61K45/06 , C07B2200/05 , C07C215/12 , C07D263/06 , C07D295/02 , C07D295/033 , C07D295/06 , C07D295/12 , C07D295/135 , C07D413/14
摘要: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
摘要翻译: 本发明涉及一种制备由结构式(I)表示的2,26,6-d4-吗啉衍生物或其盐的方法。
-
公开(公告)号:US08410082B2
公开(公告)日:2013-04-02
申请号:US13320646
申请日:2010-05-20
申请人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
CPC分类号: C07D213/81 , C07B59/002
摘要: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.
摘要翻译: 本发明涉及新的二芳基脲化合物,其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US20120237474A1
公开(公告)日:2012-09-20
申请号:US13320646
申请日:2010-05-20
申请人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
IPC分类号: C07D211/94 , A61P17/00 , A61K39/395 , A61K33/24 , A61K31/56 , A61K31/44 , A61P35/00 , A61P31/12 , A61P29/00 , A61P3/10 , A61P9/12 , A61P19/10 , A61P41/00 , A61P27/02 , A61P27/16 , A61P35/04 , A61P35/02 , A61K38/20
CPC分类号: C07D213/81 , C07B59/002
摘要: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.
摘要翻译: 本发明涉及新的二芳基脲化合物,其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
-
-
-
-
-
-
-
-